Clinical Trial Update: Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab as second-line therapy for advanced hepatocellular carcinoma after sorafenib failure has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-08-04